Description:
The Food & Drug Administration (FDA) has announced a new Risk Evaluation and Mitigation Strategy (REMS) for all extended-release and long-acting opioid medications.  Listen as ACCME Chief Executive, Murray Kopelow, MD, comments on how accredited CME can be a strategic asset to this critical public health and public safety initiative.
 
To listen to this audio file, click on the Play button ( ►) above. 
Click here to download a transcript of this recording (PDF).

Additional Resources: 
For more information about the FDA's Action on Opioid Drugs, visit http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm.  The following are documents that discuss the incorporation of CME into this REMS implementation:

• Letter Sent to Opioid Manufacturers Outlining Opioid REMS Implementation (PDF - 61KB)
• Appendix A: Content of Education Program (PDF - 37KB)

Related Content:

• 04/21/11 News Release - ACCME to Assist Providers Addressing Prescription Drug Abuse Through Accredited CME and FDA REMS

• 05/19/11 NEW Ask ACCME FAQs - Standards for Commercial Support, 1: Independence (Questions 13-21)